10x Genomics (TXG) EBT (2018 - 2026)

10x Genomics (TXG) has 9 years of EBT data on file, last reported at -$12.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 61.66% year-over-year to -$12.8 million; the trailing twelve-month figure through Mar 2026 stood at -$19.2 million (up 87.45% YoY), and the FY2025 full-year result was -$39.9 million, up 77.54% from the prior year.
• EBT improved to -$12.8 million in Q1 2026, from -$15.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $37.0 million in Q2 2025 to a low of -$91.7 million in Q3 2023.
• A 5-year average of -$37.7 million and a median of -$40.0 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT plunged 541.0% in 2022 and jumped 199.78% in 2025, its largest moves.
• Tracing TXG's EBT over 5 years: stood at -$16.4 million in 2022, then plunged by 183.94% to -$46.6 million in 2023, then fell by 3.82% to -$48.4 million in 2024, then soared by 68.6% to -$15.2 million in 2025, then advanced by 15.44% to -$12.8 million in 2026.
• Business Quant data shows TXG's EBT at -$12.8 million in Q1 2026, -$15.2 million in Q4 2025, and -$28.2 million in Q3 2025.